Navigation Links
SuperGen to Present at BIO CEO & Investor Conference on February 10, 2009
Date:2/3/2009

DUBLIN, Calif., Feb. 3 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that James S. Manuso, Ph.D., President and Chief Executive Officer, is scheduled to present at the BIO CEO & Investor Conference on February 10, 2009 at the Waldorf-Astoria in New York.

SuperGen's presentation at the BIO CEO & Investor Conference is scheduled to begin at 11:30 a.m. ET. A live webcast of the presentation will be available on the investor relations section of the Company's Web site at www.supergen.com. The webcast will be archived for 90 days.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, our ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

    Contacts:
    Timothy L. Enns
    SuperGen, Inc.
    SVP, Corporate Communications & Business Development
    Tel: (925) 560-2810
    E-mail: tenns@supergen.com

    Susanna Chau
    SuperGen, Inc.
    Investor Relations Manager
    Tel: (925) 560-2845
    E-mail: schau@supergen.com


'/>"/>
SOURCE SuperGen, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. SuperGen to Present at the Lazard Capital Markets Fifth Annual Healthcare Conference on November 18, 2008
2. SuperGen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 10, 2008
3. SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008
4. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
5. SuperGen Reports 2007 Third Quarter Financial Results
6. SuperGen to Announce 2007 Third Quarter Financial Results October 29, 2007
7. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
8. Haemacure to Present at the 11th Annual BIO CEO & Investor Conference
9. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. Danaher to Present at Barclays Capital Industrial Select Conference
11. West Pharmaceutical Services To Present at the 2009 UBS Global Healthcare Services Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology: